An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 377 participants.
Also called NCT02235909
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 377 participants
- Sponsor
- Arbor Pharmaceuticals, Inc.
- Registry
-
NCT02235909
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Brazil, Bulgaria, Colombia, Hungary, Italy, Mexico, Poland, South Africa, Türkiye, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT02235909. Randomized; triple masking; primary purpose treatment. Start 2015-03-30 (actual); primary completion 2019-11-11 (actual). Results posted on 2025-02-25.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension
- Condition
- Hypertension
- Intervention (Drug)
- Azilsartan Medoxomil Low-dose
- Intervention (Drug)
- Losartan
- Intervention (Drug)
- Placebo for Azilsartan Medoxomil
- Intervention (Drug)
- Placebo for Losartan
- Intervention (Drug)
- Azilsartan Medoxomil Medium-dose (20 mg)
- Intervention (Drug)
- Azilsartan Medoxomil High-dose (40 mg)
- Lead sponsor
- Arbor Pharmaceuticals, Inc.
Record details
- Record id
cardio:ct-nct02235909- Content hash
4848358c5a7a6ad5d3b285ecc5a43ca912bb4dbde9cb54681422c15405266f39